ForteBio has launched a new Residual Protein A Detection Kit, Dip and Read, for use on the company's Octet platform. The new assay enables drug developers to accurately identify and measure levels of Protein A with high speed and minimal hands-on time.
The company claims that Dip and Read consists of biosensors and all the reagents required to quantitate Protein A or biosimilars such as MabSelect SuRe, in the presence of human IgG.
Christopher Silva, vice president of marketing at ForteBio, said: “Protein A detection is a critical quality control step during drug development and manufacturing, but traditional methods are labor-intensive, complicated and time-consuming.
“Our new Dip and Read Residual Protein A Detection Kit offers the same sensitivity levels as existing methods, but requires significantly less hands-on time and can be completed in half the time.”
The Octet platform is based on the company’s BioLayer Interferometry (BLI) technology, which uses optical biosensors to measure multiple interactions in parallel, without the use of detection agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats.
All Octet biosensors are designed to simplify quantitation and kinetic characterization by eliminating throughput limitations of traditional SPR-based systems, said the company. The Octet biosensors are disposable, configured in a standard microplate format and are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.